Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Altos Biologics Files for Approval of Aflibercept Biosimilar
Details : ALT-L9 (aflibercept), biosimilar of Eylea, is a recombinant fusion protein which inhibits VEGF A. It is being evaluated in phase 3 clinical studies for the treatment of Neovascular (Wet) AMD.
Brand Name : ALT-L9
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 01, 2024
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALT-L9 (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Brand Name : ALT-L9
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 22, 2023
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?